Search results for "Aggregation"

showing 10 items of 566 documents

C-reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis

2018

C-reactive protein (CRP) and other inflammatory biomarkers can indicate both the severity and extent of atherosclerosis, reflecting the inflammatory nature of the disease process.1 Atherogenesis begins with an inflammatory response to vascular injury with cells and mediators initiating the healing response and later inducing growth of atherosclerotic plaques. Inflammation then increases plaque instability, promoting rupture, fissuring, or erosion—the pathogenetic milieu of thrombosis in atherothrombotic ischemic strokes.

Pathologymedicine.medical_specialtyInflammationConstriction PathologicDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansbiologyC-reactive protein intracranial atherosclerosisbusiness.industryIschemic strokesC-reactive proteinAtherosclerosismedicine.diseaseThrombosisInflammatory biomarkersC-Reactive Proteinbiology.proteinPlatelet aggregation inhibitorNeurology (clinical)Intracranial Atherosclerosismedicine.symptombusinessPlatelet Aggregation Inhibitors030217 neurology & neurosurgeryNeurology
researchProduct

156th ENMC International Workshop: desmin and protein aggregate myopathies, 9-11 November 2007, Naarden, The Netherlands.

2008

Pathologymedicine.medical_specialtyProtein aggregationBiologyDesminNeurologyMuscular DiseasesPediatrics Perinatology and Child HealthmedicineMyotilinHumansDesminNeurology (clinical)Muscle SkeletalGenetics (clinical)Neuromuscular disorders : NMD
researchProduct

121st ENMC International Workshop on Desmin and Protein Aggregate Myopathies. 7–9 November 2003, Naarden, The Netherlands

2004

The 121st European Neuromuscular Centre (ENMC)sponsored International Workshop on ‘DESMIN and Protein Aggregate Myopathies’, attended by 16 active participants from France, Germany, Poland, Spain, Sweden, the United Kingdom and the USA, was actually the fourth one in a row addressing the pathology of the muscle fibre intermediate filament desmin, its associated and similar diseases, all four [1–3] organized by Michel Fardeau and Hans H. Goebel. In his introduction, the chairman, Hans H. Goebel (Mainz), recorded the evolution of ‘Protein Aggregate Myopathies (PAM)’ which are marked by the accumulation of diverse proteins within muscle fibres as a morphologic hallmark in separate myopathies w…

Pathologymedicine.medical_specialtyProtein aggregationBiologymedicine.diseaseNemaline myopathyNeurologyPediatrics Perinatology and Child HealthmedicineCongenital muscular dystrophyMyotilinDesminNeurology (clinical)Muscle fibremedicine.symptomMyopathyIntermediate filamentGenetics (clinical)Neuromuscular Disorders
researchProduct

Perineural pattern of aggregation of cellular blue nevus: probable histoarchitectural reminiscence of histogenesis.

2008

A striking feature of cellular blue nevus consists in the presence, in its histologic picture, of numerous hypertrophic nerves and nerve-like figures, positive for histochemical and immunohistochemical methods for nerve fibers and myelin sheaths. These findings, first described in Masson's original article and repeatedly highlighted in the past for their possible histogenetic significance, are currently considered as merely coincidental. However, the thin conventional histologic sections, catching only short tracts of the nerves, preclude a correct observation of their route and do not allow us to verify if there is an architectural relationship between them and the nevus as a whole. With t…

Pathologymedicine.medical_specialtySkin NeoplasmsDermatologyHistogenesisSettore MED/08 - Anatomia PatologicaPathology and Forensic MedicineNevus BluemedicineNevusHumansskin and connective tissue diseasesBlue nevusCell AggregationNeuronsbusiness.industryCellular Blue NevusCell DifferentiationEpithelial CellsGeneral MedicineAnatomyCellular blue nevus perineural aggregation histogenesismedicine.diseasemedicine.anatomical_structureNeural differentiationSchwann Cellsmedicine.symptomSilver impregnationPerineuriumbusinessNevus cellThe American Journal of dermatopathology
researchProduct

Primary desminopathies.

2007

•  Introduction •  Desmin is an essential component of the extrasarcomeric cytoskeleton in striated muscle cells •  Distal myopathy,cardiac arrhythmias,cardiomyopathy:classical criteria of primary desminopathies •  Sub-sarcolemmal and cytoplasmic desmin-positive protein aggregates:the morphological hallmark of primary and secondary desminopathies •  The spectrum of pathogenic desmin gene mutations •  The molecular pathogenesis of primary desminopathies: some answers gained,but even more questions raised •  Diagnostic work-up to distinguish primary from secondary desminopathies •  Treatment and clinical management of primary desminopathy patients Abstract Mutations of the human desmin gene o…

Pathologymedicine.medical_specialtyintermediate filamentsCardiomyopathyReviewsgranulofilamentous materialdesmininclusion bodiesmacromolecular substancesBiologymyofibrillar myopathyprotein aggregationdesmin-related myopathySarcolemmaMuscular DiseasesmedicineMyocyteAnimalsHumansIntermediate filamentMyopathyMuscle SkeletalCytoskeletonGenetic heterogeneityCardiac muscleCell Biologymedicine.diseasemusculoskeletal systemmutationsmedicine.anatomical_structuredesminopathyMutationMolecular MedicineDesminmedicine.symptomMyofibrilJournal of cellular and molecular medicine
researchProduct

Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - …

2008

Peripheral Vascular DiseasesLegtrainingTiclopidineAspirinAcetylsalicylic acidanticoagulant agentantithrombocytic agentconsensus document; intermittent claudicatio; training; antiplatelets' therapyintermittent claudicatioIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareClopidogrelantiplatelets' therapyIschemiaDisease ProgressionExercise TestHumansCarotid StenosisUltrasonography Doppler Colorconsensus documentPlatelet Aggregation Inhibitors
researchProduct

Hemorheologic profile of hyperlipidemic patients treated with gemfibrozil

1996

Abstract We measured the plasma lipid levels and the macrorheologic (whole-blood, plasma, and serum viscosity levels; fibrinogen; hematocrit; mean erythrocyte aggregation; and whole-blood filterability) and microrheologic (erythrocyte membrane fluidity and red cell membrane protein lateral mobility) determinants in a group of 19 hyperlipidemic patients (Fredrickson's classification phenotype IIa, 12 patients; phenotype IV, 4; phenotype IIb, 3) at baseline and after 45 and 90 days of treatment with gemfibrozil (900 mg orally once a day). At baseline we noted statistically significant increases in plasma viscosity level, fibrinogen, and mean erythrocyte aggregation, as well as a statistically…

PharmacologyChemotherapymedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentHealthy subjectsSerum viscosityHematocritFibrinogenErythrocyte aggregationEndocrinologyInternal medicinePlasma lipidsmedicineGemfibrozilPharmacology (medical)businessmedicine.drugCurrent Therapeutic Research
researchProduct

Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India

2000

'Darakchasava' is a well known Indian herbal preparation of which the main ingredient is Vitis vinifera L. This 'ayurvedic' medicine is prescribed as a cardiotonic and also given for other disorders. HPLC analysis of this age old formulation revealed the presence of polyphenols like resveratrol and pterostilbene. These phenolic compounds are now known as antioxidants, cancer chemopreventive agents, and also known to reduce mortality from coronary heart disease by increasing high density lipoproteins like cholesterol and inhibiting platelet aggregation (Soleas, J.S., Diamandis, E.P., Goldberg, D.M., 1997. Resveratrol: a molecule whose time has come? and gone? Clin. Biochem. 30 (2), 91-113). …

PharmacologyPterostilbeneTraditional medicinePlant ExtractsCholesterolIndiafood and beveragesPharmacognosyResveratrolAntineoplastic Agents PhytogenicAntioxidantsMedicine Ayurvedicchemistry.chemical_compoundIngredientPhenolschemistryResveratrolPolyphenolStilbenesDrug DiscoveryHypoglycemic AgentsPlatelet aggregation inhibitorVitis viniferaChromatography High Pressure LiquidPlatelet Aggregation InhibitorsJournal of Ethnopharmacology
researchProduct

Two different aggregation principles in reaggregation process of dissociated sponge cells (Geodia cydonium)

1974

Chemisch dissoziierte Zellen des KieselschwammesGeodia cydonium reaggregieren aufgrund zweier verschiedenr Reaggregationsprinzipien. Der Aggnegationsfaktor, auf den die Primaraggregation zuruckgeht, ist membrangebunden und wird durch Proteasen nicht inaktiviert. Der sekundare Aggregationsfaktor wurde 500fach angereichert. Das Molekulargewicht dieses Aggregationsfaktors betragt etwa 20000 Daltons; er ist mit einem ringformigen Makromolekul (2×109 Daltons) assoziiert.

PharmacologybiologySurface PropertiesChemistryGeodia cydoniumCarboxypeptidasesCell Biologybiology.organism_classificationMolecular biologyPoriferaMicroscopy ElectronCellular and Molecular NeuroscienceSpongeCell AdhesionBiophysicsAnimalsMolecular MedicineGeodiaMolecular BiologyCell AggregationExperientia
researchProduct

Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat

1997

1 The effects of YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole), an activator of soluble guanylyl cyclase, on tension, levels of cyclic GMP and cyclic AMP, and cardiac L-type Ca2+-current (ICa(L)) were investigated in aortic smooth muscle and ventricular heart muscle from rat. 2 YC-1 (0.1–30 μM) induced a concentration-dependent relaxation in aortic rings precontracted with phenylephrine (3 μM). The relaxant effects of YC-1 were reversed by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (30 μM; ODQ), potentiated by zaprinast (10 μM) and antagonized by Rp-8-Br-cGMPS (100 μM). 3 In ventricular heart muscle strips, YC-1 (30 μM) exhibited no effects on force of contraction (Fc) in the abse…

Pharmacologymedicine.medical_specialtyAortaContraction (grammar)Chemistrychemistry.chemical_compoundEndocrinologyIsoprenalineInternal medicinemedicine.arterycardiovascular systemmedicinePlatelet aggregation inhibitormedicine.symptomSoluble guanylyl cyclaseZaprinastPhenylephrineVasoconstrictionmedicine.drugBritish Journal of Pharmacology
researchProduct